1. Clinical and gene mutation features of cystic fibrosis: an analysis of 8 cases.
- Author
-
ZHANG Na, LIU Jian-Hua, CHU Ya-Juan, SHUAI Jin-Feng, and HUANG Kun-Ling
- Subjects
BRONCHIECTASIS ,CYSTIC fibrosis ,GENETIC mutation ,RESPIRATORY infections in children ,FRAMESHIFT mutation ,NONSENSE mutation - Abstract
Objective To study the clinical features and gcnc mutation sites of children with cystic fibrosis (CF), in order to improve the understanding of CF to reduce misdiagnosis and missed diagnosis. Methods A retrospective analysis was performed on the medical records of 8 children with CF who were diagnosed in Hebei Children's Hospital from 2018 to 2021. Results Among the 8 children with CF, there were 5 boys and 3 girls, with an age of 3-48 months (median 8 months) at diagnosis, and the age of onset ranged from 0 to 24 months (median 2.5 months). Clinical manifestations included recurrent respiratory infection in 7 children, sinusitis in 3 children, bronchiectasis in 4 children, diarrhea in 8 children, fatty diarrhea in 3 children, suspected pancreatic insufficiency in 6 children, pancreatic cystic fibrosis in 1 child, malnutrition in 5 children, and pseudo-Bartter syndrome in 4 children. The most common respiratory pathogens were Pseudomonas aeruginosa (4 children). A total of 16 mutation sites were identified by high-throughput sequencing, multiplex ligation-dependent probe amplification, and Sanger sequencing, including 5 frameshift mutations, 4 nonsense mutations, 4 misscnsc mutations, 2 cxon deletions, and 1 splice mutation. CFTR mutations were found in all 8 children. p.G970D was the most common mutation (3 children), and F508del mutation was observed in one child. Four novel mutations were noted: deletion exon15, c. 3796_3797dupGA(p. I1267Kfs*12), c. 2328dupA(p. V777Sfs*2), and c. 2950G>A(p. D984N). Conclusions p. G970D is the most common mutation type in children with CF. CF should be considered for children who have recurrent respiratory infection or test positive for Pseudomonas aeruginosa, with or without digestive manifestations or pseudo-Bartter syndrome. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF